vs
自然阳光（NATR）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是自然阳光的1.5倍（$179.7M vs $123.8M），自然阳光净利率更高（3.3% vs -29.5%，领先32.8%），Rocket Lab Corp同比增速更快（35.7% vs 4.7%），自然阳光自由现金流更多（$7.6M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 5.6%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
NATR vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.5倍
$123.8M
营收增速更快
RKLB
高出31.0%
4.7%
净利率更高
NATR
高出32.8%
-29.5%
自由现金流更多
NATR
多$121.7M
$-114.2M
两年增速更快
RKLB
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $179.7M |
| 净利润 | $4.1M | $-52.9M |
| 毛利率 | 72.5% | 38.0% |
| 营业利润率 | 4.3% | -28.4% |
| 净利率 | 3.3% | -29.5% |
| 营收同比 | 4.7% | 35.7% |
| 净利润同比 | 1379.4% | -1.1% |
| 每股收益（稀释后） | $0.23 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRRKLB
| Q4 25 | $123.8M | $179.7M | ||
| Q3 25 | $128.3M | $155.1M | ||
| Q2 25 | $114.8M | $144.5M | ||
| Q1 25 | $113.2M | $122.6M | ||
| Q4 24 | $118.2M | $132.4M | ||
| Q3 24 | $114.6M | $104.8M | ||
| Q2 24 | $110.6M | $106.3M | ||
| Q1 24 | $111.0M | $92.8M |
净利润NATRRKLB
| Q4 25 | $4.1M | $-52.9M | ||
| Q3 25 | $5.3M | $-18.3M | ||
| Q2 25 | $5.3M | $-66.4M | ||
| Q1 25 | $4.7M | $-60.6M | ||
| Q4 24 | $-321.0K | $-52.3M | ||
| Q3 24 | $4.3M | $-51.9M | ||
| Q2 24 | $1.3M | $-41.6M | ||
| Q1 24 | $2.3M | $-44.3M |
毛利率NATRRKLB
| Q4 25 | 72.5% | 38.0% | ||
| Q3 25 | 73.3% | 37.0% | ||
| Q2 25 | 71.7% | 32.1% | ||
| Q1 25 | 72.1% | 28.8% | ||
| Q4 24 | 72.0% | 27.8% | ||
| Q3 24 | 71.3% | 26.7% | ||
| Q2 24 | 71.4% | 25.6% | ||
| Q1 24 | 71.2% | 26.1% |
营业利润率NATRRKLB
| Q4 25 | 4.3% | -28.4% | ||
| Q3 25 | 7.0% | -38.0% | ||
| Q2 25 | 3.7% | -41.3% | ||
| Q1 25 | 5.4% | -48.3% | ||
| Q4 24 | 3.8% | -38.9% | ||
| Q3 24 | 4.6% | -49.5% | ||
| Q2 24 | 5.1% | -40.7% | ||
| Q1 24 | 4.2% | -46.4% |
净利率NATRRKLB
| Q4 25 | 3.3% | -29.5% | ||
| Q3 25 | 4.2% | -11.8% | ||
| Q2 25 | 4.6% | -46.0% | ||
| Q1 25 | 4.2% | -49.5% | ||
| Q4 24 | -0.3% | -39.5% | ||
| Q3 24 | 3.8% | -49.6% | ||
| Q2 24 | 1.2% | -39.2% | ||
| Q1 24 | 2.1% | -47.7% |
每股收益（稀释后）NATRRKLB
| Q4 25 | $0.23 | $-0.09 | ||
| Q3 25 | $0.30 | $-0.03 | ||
| Q2 25 | $0.28 | $-0.13 | ||
| Q1 25 | $0.25 | $-0.12 | ||
| Q4 24 | $-0.02 | $-0.11 | ||
| Q3 24 | $0.23 | $-0.10 | ||
| Q2 24 | $0.07 | $-0.08 | ||
| Q1 24 | $0.12 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $161.6M | $1.7B |
| 总资产 | $261.1M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资NATRRKLB
| Q4 25 | $93.9M | $1.0B | ||
| Q3 25 | $95.6M | $976.7M | ||
| Q2 25 | $81.3M | $688.1M | ||
| Q1 25 | $86.5M | $428.4M | ||
| Q4 24 | $84.7M | $419.0M | ||
| Q3 24 | $78.7M | $442.4M | ||
| Q2 24 | $68.7M | $496.8M | ||
| Q1 24 | $77.8M | $492.5M |
总债务NATRRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | $2.1M | $66.8M |
股东权益NATRRKLB
| Q4 25 | $161.6M | $1.7B | ||
| Q3 25 | $166.7M | $1.3B | ||
| Q2 25 | $163.7M | $688.5M | ||
| Q1 25 | $167.1M | $431.3M | ||
| Q4 24 | $161.0M | $382.5M | ||
| Q3 24 | $162.6M | $419.8M | ||
| Q2 24 | $156.4M | $455.2M | ||
| Q1 24 | $159.7M | $478.9M |
总资产NATRRKLB
| Q4 25 | $261.1M | $2.3B | ||
| Q3 25 | $264.8M | $2.2B | ||
| Q2 25 | $254.9M | $1.6B | ||
| Q1 25 | $252.7M | $1.3B | ||
| Q4 24 | $240.9M | $1.2B | ||
| Q3 24 | $245.3M | $1.2B | ||
| Q2 24 | $235.8M | $1.2B | ||
| Q1 24 | $247.3M | $1.2B |
负债/权益比NATRRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | 0.01× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | $-114.2M |
| 自由现金流率自由现金流/营收 | 6.1% | -63.6% |
| 资本支出强度资本支出/营收 | 1.9% | 27.6% |
| 现金转化率经营现金流/净利润 | 2.41× | — |
| 过去12个月自由现金流最近4个季度 | $28.8M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流NATRRKLB
| Q4 25 | $9.9M | $-64.5M | ||
| Q3 25 | $18.5M | $-23.5M | ||
| Q2 25 | $4.3M | $-23.2M | ||
| Q1 25 | $2.6M | $-54.2M | ||
| Q4 24 | $12.2M | $-2.4M | ||
| Q3 24 | $9.6M | $-30.9M | ||
| Q2 24 | $1.3M | $-13.0M | ||
| Q1 24 | $2.2M | $-2.6M |
自由现金流NATRRKLB
| Q4 25 | $7.6M | $-114.2M | ||
| Q3 25 | $16.8M | $-69.4M | ||
| Q2 25 | $3.0M | $-55.3M | ||
| Q1 25 | $1.5M | $-82.9M | ||
| Q4 24 | $10.0M | $-23.9M | ||
| Q3 24 | $7.9M | $-41.9M | ||
| Q2 24 | $-2.0M | $-28.3M | ||
| Q1 24 | $-1.5M | $-21.8M |
自由现金流率NATRRKLB
| Q4 25 | 6.1% | -63.6% | ||
| Q3 25 | 13.1% | -44.8% | ||
| Q2 25 | 2.6% | -38.3% | ||
| Q1 25 | 1.3% | -67.6% | ||
| Q4 24 | 8.5% | -18.1% | ||
| Q3 24 | 6.9% | -40.0% | ||
| Q2 24 | -1.9% | -26.7% | ||
| Q1 24 | -1.4% | -23.5% |
资本支出强度NATRRKLB
| Q4 25 | 1.9% | 27.6% | ||
| Q3 25 | 1.3% | 29.6% | ||
| Q2 25 | 1.2% | 22.2% | ||
| Q1 25 | 1.0% | 23.4% | ||
| Q4 24 | 1.9% | 16.3% | ||
| Q3 24 | 1.5% | 10.5% | ||
| Q2 24 | 3.0% | 14.4% | ||
| Q1 24 | 3.3% | 20.7% |
现金转化率NATRRKLB
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
